- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05928546
Effect of Quercetin in Treatment of Periodontitis
January 29, 2024 updated by: Alzahraa Alghriany, Assiut University
Efficacy of Quercetin Nanoemulgel as Adjunct Local Delivery Drug in Non-surgical Treatment of Periodontitis
Periodontitis is an immune-inflammatory disease affecting the supporting structures of the teeth.
It is a disease of multifactorial etiology, with microbial, genetic, environmental and host factors involved, with the release of oxygen-free radicals by the inflammatory cells.
Quercetin, have shown potential antimicrobial activity, lowering of inflammatory markers, cholesterol reduction and inhibiting bone loss.
However, this data has largely been obtained from in vitro and animal studies, but data from human studies are limited.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Quercetin has been found to decrease the extracellular matrix degradation, promote wound healing when tested in gingival fibroblasts, and showed excellent antibacterial properties.
It also possesses antioxidant effect which can be explored to restrict the inflammation in periodontitis.
Despite the beneficial effects of Quercetin, its poor aqueous solubility and poor bioavailability result in limited absorption, so scientists have worked on improving the bioavailability of Quercetin using various approaches, such as nanosuspension , self-nano emulsifying systems , microemulsion , solid lipid nanoparticles and cyclodextrin complexes.
The combination of oils and emulsifiers enhances the absorption of Quercetin.
Hence, nanoemulsion could be a suitable drug delivery vehicle for the loading of Quercetin.
Nanoemulsions are more beneficial than microemulsions, as they have high kinetic stability and a smaller droplet size.
Therefore, the present study will investigate the efficacy of nanoemulgel of quercetin as adjunct to conventional therapy in treatment of periodontitis.
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Alzahraa Ahmed Alghriany, lecturer
- Phone Number: +201203770058
- Email: alghriany@aun.edu.eg
Study Contact Backup
- Name: Ahmed Mortada, professor
- Phone Number: +201005432223
- Email: mortadafikry@hotmail.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Inclusion criteria:
- Patients with periodontitis stage ( Ⅰ & Ⅱ ). Stage I have CAL 1 to 2mm with no tooth loss and probing depth ≤4 mm. Stage II have CAL 3 to 4mm with no tooth loss and probing depth ≤5 mm..
- Patients who have teeth with both mesial and distal neighboring teeth .
- Patient with more than 20 natural teeth .
- Patient free from any systemic disease that may effect the periodontal status according to the criteria of Cornell Medical Index and its modification.
Exclusion Criteria:
- Long-term therapy with medications within a month prior to enrollment that could affect periodontal status or healing.
- Pregnant woman and lactating mothers .
- Patients with a history of traumatic occlusion.
- Teeth with both endo-perio lesion .
- Patients with previous periodontal treatment including scaling and root planing and periodontal surgery in the last 3 and 6 months, respectively .
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Group(I):scaling and root planing only
10 sites will receive non-surgical periodontal therapy (scaling and root planing) .
|
- Full-mouth scaling and root planing was performed in 1-2 sessions within 2 weeks using manual scalers and curettes or ultrasonic scaler and local anesthesia was used in case of need for patient comfort.
|
|
Active Comparator: Group(Ⅱ):scaling and root planing with application of quercetin nanoemulgel
10 sites will receive non-surgical periodontal therapy followed by the application of quercetin nanoemulgel local delivery 2 times one at the day of non-surgical periodontal therapy and after 2 weeks.
|
- Full-mouth scaling and root planing was performed in 1-2 sessions within 2 weeks using manual scalers and curettes or ultrasonic scaler and local anesthesia was used in case of need for patient comfort.
Intra-pocket application of quercetin nanoemulgel :
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the changes in the clinical attachment loss
Time Frame: at base line, 1 month and 3 months after treatment
|
Attachment level was measured using UNC15(University of North Carolina) periodontal probe.
Clinical attachment loss was measured as the distance from the cemento-enamel junction to the base of the pocket.
|
at base line, 1 month and 3 months after treatment
|
|
Probing depth
Time Frame: at base line, 1 month and 3 months after treatment
|
The measurement were recorded by UNC15(University of North Carolina) periodontal probe .
Pocket depth was measured as the distances from the free gingival margin to the base of the periodontal pocket.
|
at base line, 1 month and 3 months after treatment
|
|
interferon IFN-γ analysis
Time Frame: at base line, 1 month and 3 months after treatment
|
The samples were assayed for (IFN-γ) levels using commercially available enzyme-linked immune-sorbent assay (ELISA) .
Highly sensitive ELISA kit was used to detect the (IFN-γ) level in pg/ml in the sample of GCF according to the manufacturer's instructions.
|
at base line, 1 month and 3 months after treatment
|
|
reactive oxygen species (ROS)
Time Frame: at base line, 1 month and 3 months after treatment
|
The samples were assayed for antioxidant effect of quercetin using commercially available reactive oxygen species( ROS) kit .
Highly sensitive ROS kit was used according to the manufacturer's instruction
|
at base line, 1 month and 3 months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plaque index (PI)
Time Frame: at base line, 1 month and 3 months after treatment
|
It used to assess plaque accumulation around gingival margin. The degree of plaque accumulation was recorded as follow:
|
at base line, 1 month and 3 months after treatment
|
|
Gingival index (GI)
Time Frame: at base line, 1 month and 3 months after treatment
|
It used to assess gingival inflammation. The degree of gingival inflammation was recorded as follow:
|
at base line, 1 month and 3 months after treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ahmed Mortada Fikry, professor, Assiut University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Kantarci A, Van Dyke TE. Lipoxin signaling in neutrophils and their role in periodontal disease. Prostaglandins Leukot Essent Fatty Acids. 2005 Sep-Oct;73(3-4):289-99. doi: 10.1016/j.plefa.2005.05.019.
- Gao L, Liu G, Wang X, Liu F, Xu Y, Ma J. Preparation of a chemically stable quercetin formulation using nanosuspension technology. Int J Pharm. 2011 Feb 14;404(1-2):231-7. doi: 10.1016/j.ijpharm.2010.11.009. Epub 2010 Nov 17.
- Gomez-Florit M, Monjo M, Ramis JM. Quercitrin for periodontal regeneration: effects on human gingival fibroblasts and mesenchymal stem cells. Sci Rep. 2015 Nov 12;5:16593. doi: 10.1038/srep16593.
- Wei Y, Fu J, Wu W, Ma P, Ren L, Yi Z, Wu J. Quercetin Prevents Oxidative Stress-Induced Injury of Periodontal Ligament Cells and Alveolar Bone Loss in Periodontitis. Drug Des Devel Ther. 2021 Aug 12;15:3509-3522. doi: 10.2147/DDDT.S315249. eCollection 2021.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
February 20, 2024
Primary Completion (Estimated)
May 20, 2024
Study Completion (Estimated)
May 30, 2024
Study Registration Dates
First Submitted
June 13, 2023
First Submitted That Met QC Criteria
June 23, 2023
First Posted (Actual)
July 3, 2023
Study Record Updates
Last Update Posted (Actual)
January 31, 2024
Last Update Submitted That Met QC Criteria
January 29, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Quercetin in periodontitis
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation Gum
-
YSLabCompleted
-
The University of Hong KongActive, not recruitingPeriodontal Diseases | Oral Hygiene, Oral Health | Gum InflammationHong Kong
-
Giresun UniversityCompletedControl Group | Xylitol Gum Chewing | Non-xylitol Gum ChewingTurkey
-
University of TromsoPublic Dental Service Competence Center of Northern NorwayCompletedInflammation | Periodontitis | Periodontal Diseases | Vitamin D | Periodontal Inflammation | Inflammation GumNorway
-
University of TriesteRecruitingCardiac Surgery | Inflammation GumItaly
-
Johnson & Johnson Consumer and Personal Products...University of TaubateCompletedBleeding | Gingivitis | Plaque | Gum InflammationBrazil
-
Catherine GiannopoulouUniversity of Geneva, SwitzerlandRecruitingWhite Spot Lesion | Inflammation GumSwitzerland
-
Procter and GambleCompleted
-
Rajavithi HospitalCompleted
-
Kasr El Aini HospitalUnknownBowel Function | Gum ChewingEgypt
Clinical Trials on scaling and root planing
-
University of NebraskaCompletedPeriodontal Diseases | Periodontitis, Apical, Chronic Nonsuppurative | Suppuration of Gingival CreviceUnited States
-
University of CataniaCompletedPeriodontal DiseasesItaly
-
Institut Straumann AGCompleted
-
Mohammed Bin Rashid University of Medicine and...RecruitingPeriodontal DiseasesUnited Arab Emirates
-
University of BaghdadNot yet recruiting
-
Kutahya Health Sciences UniversityCompletedPeriodontitis | Gingivitis | Dental Anxiety | Dental Fear | Calculus, DentalTurkey
-
University of MessinaCompleted
-
University of MichiganCompletedPeriodontal Diseases | Dental DiseasesUnited States
-
Dr.K.Sai PriyankaPanineeya Mahavidyalaya Institute of Dental Sciences & Research CentreCompletedGingivitis and Periodontal Diseases
-
Panineeya Mahavidyalaya Institute of Dental Sciences...CompletedChronic Periodontitis | Renal Insufficiency Chronic